Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2006

ReNeuron Inks Collaboration Agreement with CellSeed

  • ReNeuron and CellSeed signed a collaboration agreement to develop liver-cell culture systems for drug safety screening in the pharmaceutical industry.

    The development work, to be conducted in CellSeed’s laboratories in Tokyo, will establish protocols for developing ReNeuron’s ReNcell™ HEP hepatocyte cell-lines in combination with CellSeed’s UpCell and HydroCell temperature-sensitive polymer products for 3-D functional liver tissue.

    3-D liver culture systems represent a way to assay for human liver toxicity of new drugs. The collaboration will enable the joint development of human cell-based drug discovery products for use in the pharmaceutical industry.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »